Vanguard Group Inc. Sells 65,227 Shares of Madrigal Pharmaceuticals, Inc. $MDGL

Vanguard Group Inc. trimmed its position in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) by 3.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,812,054 shares of the biopharmaceutical company’s stock after selling 65,227 shares during the period. Vanguard Group Inc. owned approximately 8.16% of Madrigal Pharmaceuticals worth $831,117,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in MDGL. Assetmark Inc. lifted its holdings in shares of Madrigal Pharmaceuticals by 3.3% during the third quarter. Assetmark Inc. now owns 5,058 shares of the biopharmaceutical company’s stock valued at $2,320,000 after acquiring an additional 160 shares during the period. Rhumbline Advisers boosted its position in Madrigal Pharmaceuticals by 3.4% in the third quarter. Rhumbline Advisers now owns 27,263 shares of the biopharmaceutical company’s stock valued at $12,504,000 after buying an additional 900 shares in the last quarter. Baader Bank Aktiengesellschaft acquired a new position in Madrigal Pharmaceuticals in the third quarter valued at about $885,000. Bryce Point Capital LLC bought a new stake in Madrigal Pharmaceuticals during the third quarter worth about $536,000. Finally, Smartleaf Asset Management LLC increased its holdings in shares of Madrigal Pharmaceuticals by 143.1% during the third quarter. Smartleaf Asset Management LLC now owns 124 shares of the biopharmaceutical company’s stock worth $55,000 after buying an additional 73 shares in the last quarter. Institutional investors and hedge funds own 98.50% of the company’s stock.

Key Madrigal Pharmaceuticals News

Here are the key news stories impacting Madrigal Pharmaceuticals this week:

• Positive Sentiment: Rezdiffra commercial strength: Q4 net sales of roughly $321.1M (Q4) and $958.4M for full‑year 2025, more than 36,250 patients on therapy and nearly $989M in cash and marketable securities — evidence of strong revenue growth and a sizeable cash runway. Press Release
• Neutral Sentiment: Investor materials and transparency: company provided an earnings slide deck and held a conference call — useful for modeling future margins, guidance and pipeline milestones. Earnings Presentation
• Negative Sentiment: Large EPS miss and rising expenses: reported Q4 EPS of ($2.57) vs. consensus ~$0.04, driven by a wider loss as expenses surged despite revenue beating estimates — this prompted an immediate negative market reaction. Zacks Article
• Negative Sentiment: Analyst action: Bank of America cut its price target (from $570 to $529) and set a “neutral” rating, reducing near‑term upside expectations and likely contributing to selling pressure. Benzinga

Insider Buying and Selling

In other news, CEO William John Sibold sold 2,400 shares of Madrigal Pharmaceuticals stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $575.34, for a total transaction of $1,380,816.00. Following the completion of the sale, the chief executive officer owned 150,074 shares in the company, valued at $86,343,575.16. The trade was a 1.57% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Rebecca Taub sold 18,650 shares of the stock in a transaction that occurred on Wednesday, December 10th. The shares were sold at an average price of $552.15, for a total transaction of $10,297,597.50. Following the completion of the transaction, the director owned 461,044 shares in the company, valued at $254,565,444.60. This represents a 3.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 99,537 shares of company stock worth $53,485,702. 21.50% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

MDGL has been the topic of several recent analyst reports. Barclays initiated coverage on Madrigal Pharmaceuticals in a report on Tuesday, January 27th. They issued an “overweight” rating and a $964.00 target price on the stock. The Goldman Sachs Group reissued a “buy” rating and issued a $571.00 price objective on shares of Madrigal Pharmaceuticals in a research note on Wednesday, January 14th. Citizens Jmp increased their target price on Madrigal Pharmaceuticals from $527.00 to $745.00 and gave the stock a “market outperform” rating in a report on Tuesday, January 20th. Truist Financial lifted their price target on Madrigal Pharmaceuticals from $580.00 to $640.00 and gave the company a “buy” rating in a report on Wednesday, November 19th. Finally, Citigroup reiterated an “outperform” rating on shares of Madrigal Pharmaceuticals in a research report on Tuesday, January 20th. One research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Madrigal Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $669.86.

Madrigal Pharmaceuticals Stock Down 0.4%

NASDAQ MDGL opened at $435.01 on Monday. The stock has a market capitalization of $9.98 billion, a P/E ratio of -33.80, a price-to-earnings-growth ratio of 20.03 and a beta of -1.01. Madrigal Pharmaceuticals, Inc. has a 52 week low of $265.00 and a 52 week high of $615.00. The company has a debt-to-equity ratio of 0.56, a quick ratio of 3.77 and a current ratio of 4.01. The stock has a fifty day moving average of $521.61 and a 200-day moving average of $483.32.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last posted its quarterly earnings results on Thursday, February 19th. The biopharmaceutical company reported ($2.57) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($2.61). The firm had revenue of $321.08 million during the quarter, compared to the consensus estimate of $310.36 million. Madrigal Pharmaceuticals had a negative net margin of 30.08% and a negative return on equity of 43.76%. Madrigal Pharmaceuticals’s revenue was up 210.8% on a year-over-year basis. During the same quarter in the prior year, the business earned ($2.71) EPS. On average, equities research analysts forecast that Madrigal Pharmaceuticals, Inc. will post -23.47 EPS for the current year.

Madrigal Pharmaceuticals Profile

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.